Zhi Tong Cai Jing·2026-02-04 10:08Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of its Sitagliptin Metformin Extended-Release Tablets, which is expected to enhance market share and competitiveness in the diabetes treatment sector [1] Group 1: Product Approval - The Sitagliptin Metformin Extended-Release Tablets are intended for adult patients with type 2 diabetes who are currently receiving combined treatment with Sitagliptin and Metformin [1] - The product was originally developed by Merck Sharp & Dohme and was launched in the United States in 2012 [1] - The application for registration was submitted to the National Medical Products Administration in June 2024 and has been accepted [1] Group 2: Financial Investment - The company has invested approximately RMB 8.49 million in research and development for this product [1] Group 3: Market Impact - According to national policies, newly registered generic drugs will receive greater support in areas such as medical insurance payments and procurement by medical institutions [1] - The approval of the Sitagliptin Metformin Extended-Release Tablets is expected to help expand market share and improve competitiveness [1] - The experience gained from this approval will be valuable for the company's future generic drug applications [1]